Scholarlink

<p>Lanreotide is a synthetic polypeptide analog of somatostatin that is used to treat gastroenteropancreatic neuroendocrine tumors (NETs). Although granulomatous inflammation is caused by a variety of conditions, lanreotide acetate subcutaneous injection-induced granulomatous inflammation has not been reported. A 53-year-old woman was underwent extirpation for NET on the anterior surface of pancreatic head. The pathological findings revealed that the resected specimen mainly consisted of lymph-node metastasis and diagnosed NET of unknown primary origin. Because there was a possibility of remnant of the primary tumor and a high risk of recurrence, she began monthly lanreotide acetate subcutaneous injections 1&#xa0;month after NET surgery. Diffusion-weighted whole-body imaging with background signal suppression revealed a subcutaneous nodule with a high signal in the left buttock 2&#xa0;months after surgery, which was suggestive of NET subcutaneous metastasis. A computed tomography scan 5&#xa0;months after surgery revealed multiple subcutaneous nodules on the buttocks bilaterally. Because the number of subcutaneous nodules on the buttocks increased over time, an excisional biopsy of the nodule was obtained. The subcutaneous nodule was diagnosed as granulomatous inflammation based on the histopathologic evaluation. Clinicians should be aware that subcutaneous injection of lanreotide acetate may cause granulomatous inflammation, resulting in subcutaneous nodules that may be misdiagnosed as subcutaneous metastases.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Lanreotide acetate subcutaneous injection-induced granulomatous inflammation after surgery for neuroendocrine tumor of unknown primary origin

  • 期刊论文

  • 发表日期：

    2025年11月4日

查看全文
  • Susumu Saigusa,
  • Hiroyuki Sakurai,
  • Hiroyuki Fujikawa,
  • Shuyo Watanabe,
  • Kosuke Fukumochi,
  • Yo Uchiyama,
  • Tomomi Mohri,
  • Yoshifumi Hirokawa,
  • Koji Tanaka

摘要

Lanreotide is a synthetic polypeptide analog of somatostatin that is used to treat gastroenteropancreatic neuroendocrine tumors (NETs). Although granulomatous inflammation is caused by a variety of conditions, lanreotide acetate subcutaneous injection-induced granulomatous inflammation has not been reported. A 53-year-old woman was underwent extirpation for NET on the anterior surface of pancreatic head. The pathological findings revealed that the resected specimen mainly consisted of lymph-node metastasis and diagnosed NET of unknown primary origin. Because there was a possibility of remnant of the primary tumor and a high risk of recurrence, she began monthly lanreotide acetate subcutaneous injections 1 month after NET surgery. Diffusion-weighted whole-body imaging with background signal suppression revealed a subcutaneous nodule with a high signal in the left buttock 2 months after surgery, which was suggestive of NET subcutaneous metastasis. A computed tomography scan 5 months after surgery revealed multiple subcutaneous nodules on the buttocks bilaterally. Because the number of subcutaneous nodules on the buttocks increased over time, an excisional biopsy of the nodule was obtained. The subcutaneous nodule was diagnosed as granulomatous inflammation based on the histopathologic evaluation. Clinicians should be aware that subcutaneous injection of lanreotide acetate may cause granulomatous inflammation, resulting in subcutaneous nodules that may be misdiagnosed as subcutaneous metastases.